Compare Bajaj Finserv Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.37 | 1.86 |
NAV | ₹9.59 | ₹38.47 |
Fund Started | 06 Dec 2024 | 25 Jun 2018 |
Fund Size | ₹338.55 Cr | ₹6455.55 Cr |
Exit Load | 1% for redemption within 3 Months | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.37
1.86
NAV
₹9.59
₹38.47
Fund Started
06 Dec 2024
25 Jun 2018
Fund Size
₹338.55 Cr
₹6455.55 Cr
Exit Load
1% for redemption within 3 Months
Exit load of 1% if redeemed within 15 days.
1 Year | - | 0.60% |
3 Year | - | 26.13% |
5 Year | - | 16.47% |
1 Year
-
0.60%
3 Year
-
26.13%
5 Year
-
16.47%
Equity | 95.25% | 97.87% |
Cash | 0.41% | 2.13% |
Equity
95.25%
97.87%
Cash
0.41%
2.13%
Top 10 Holdings |
|
|
Top 10 Holdings
Divi's Laboratories Ltd. | 8.41% |
Sun Pharmaceutical Industries Ltd. | 8.24% |
Apollo Hospitals Enterprise Ltd. | 5.93% |
Aurobindo Pharma Ltd. | 5.54% |
Cipla Ltd. | 5.06% |
Piramal Pharma Ltd. | 4.40% |
Neuland Laboratories Ltd. | 4.26% |
Biocon Ltd. | 4.00% |
Emcure Pharmaceuticals Ltd. | 3.43% |
Fortis Healthcare Ltd. | 3.26% |
Sun Pharmaceutical Industries Ltd. | 12.05% |
Cipla Ltd. | 7.90% |
Dr. Reddy's Laboratories Ltd. | 7.82% |
Divi's Laboratories Ltd. | 7.10% |
Mankind Pharma Ltd. | 6.44% |
Lupin Ltd. | 5.78% |
Aurobindo Pharma Ltd. | 5.19% |
Alkem Laboratories Ltd. | 3.66% |
Cohance Lifesciences Ltd. | 3.01% |
Syngene International Ltd. | 2.98% |
Name | Sorbh Gupta | - |
Start Date | 10 Nov 2025 | - |
Name
Sorbh Gupta
-
Start Date
10 Nov 2025
-
Description | The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 06 Dec 2024 | 25 Jun 2018 |
Description
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
06 Dec 2024
25 Jun 2018